Hair Care
GLP-1 Drugs and Bone Density
Studies on GLP-1 medication and bone health genuinely disagree with each other. Here is why, and what that means for any...
This connects directly to the gastroparesis and delayed gastric emptying topics covered elsewhere in this series, applied to a specific and genuinely important situation: any procedure requiring sedation or general anaesthesia.
Why this matters
GLP-1 medication slows gastric emptying, which is the core mechanism behind how it works. Standard pre-surgical fasting guidance, commonly instructing patients not to eat solid food for a set number of hours beforehand, was developed assuming normal gastric emptying rates.
If your stomach empties more slowly than usual, standard fasting instructions may not guarantee your stomach is actually empty by the time anaesthesia begins. This creates a genuine risk of aspiration, where stomach contents enter the lungs during the procedure, a serious anaesthetic complication.
This risk was covered in our guide to gastroparesis, and it applies to a wider range of situations than severe gastroparesis specifically, since even the ordinary slowed emptying these drugs produce as intended can be relevant here.
What has changed in anaesthetic guidance
Anaesthetic societies and regulatory bodies in several countries have specifically addressed GLP-1 medication in updated pre-operative guidance, recognising this as a genuine and previously underappreciated risk given how rapidly use of this drug class has expanded.
Approaches vary, but commonly include recommendations for extended fasting periods, holding the medication for a period before the procedure, using additional precautions during induction of anaesthesia such as treating the patient as though the stomach may not be empty regardless of standard fasting compliance, or in some cases, using imaging to directly assess stomach contents before proceeding.
The specific guidance you should follow depends on your anaesthetic team's current protocol, which is precisely why disclosure matters so much.
The disclosure problem
This is the single most important practical point in this article.
Many patients do not think to mention GLP-1 medication when asked about their medical history before a procedure, particularly if they are taking it for weight loss rather than diagnosed diabetes, or if they consider it a supplement rather than a medication requiring disclosure.
Do not assume it is already on your medical notes. Explicitly tell your surgeon and your anaesthetist that you are taking GLP-1 medication, at every relevant appointment, including pre-operative assessment, even for procedures that seem minor, such as dental work under sedation or a routine endoscopy.
What this means for planning
If a procedure is scheduled, raise your GLP-1 medication with the surgical and anaesthetic team as early as possible, ideally at the initial consultation rather than only on the day.
Follow their specific guidance on whether to hold the medication beforehand and for how long. This is not something to decide independently based on general information, since the appropriate approach depends on your specific medication, dose, and the type of procedure.
Be prepared for extended fasting instructions beyond what might be standard for someone not on this medication.
If your procedure is urgent or emergency, ensure the team is told about your GLP-1 medication use even without advance planning time, since the same aspiration risk consideration applies.
Elective procedures specifically
For elective procedures where timing has some flexibility, this is also worth factoring into planning around your weight loss treatment more broadly.
Some people choose to plan elective procedures around dose escalation phases, avoiding scheduling major surgery during a period of active side effects or dose changes, though this is a discussion for your surgical team rather than a rule to apply independently.
Where this applies to supplements too
The underlying mechanism, slowed gastric emptying, is what matters for this risk, not specifically which pharmaceutical brand you take. Physician-reviewed sublingual drops work on the GLP-1 pathway and, while formulated differently and delivered sublingually rather than by injection, the same disclosure principle applies: tell your surgical team about any GLP-1 pathway product you are taking, including METASLIM™, which is a physician-reviewed supplement rather than a pharmaceutical GLP-1 receptor agonist.
A JAMA review of gastrointestinal adverse events associated with this drug class provides useful context for why this class of effects is taken seriously in a surgical setting specifically.
If you have a procedure coming up and are unsure how any GLP-1 pathway product fits into your surgical planning, check the current price and what's included and raise the question directly during the physician review.
The summary
Slowed gastric emptying from GLP-1 medication means standard pre-surgical fasting guidance may not guarantee an empty stomach, creating aspiration risk during anaesthesia.
Anaesthetic bodies in several countries now provide specific guidance addressing this, commonly involving extended fasting or holding medication beforehand.
Many patients do not think to disclose GLP-1 medication use, particularly if taking it for weight loss rather than diagnosed diabetes.
Tell your surgical and anaesthetic team explicitly, at every relevant appointment, even for procedures that seem minor.
Follow their specific guidance on timing rather than deciding independently.
Talk to our team if you have questions about how this applies to appetite support specifically before a scheduled procedure.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.